Literature DB >> 1965141

Expression of glycolipid receptors to Shiga-like toxin on human B lymphocytes: a mechanism for the failure of long-lived antibody response to dysenteric disease.

A Cohen1, V Madrid-Marina, Z Estrov, M H Freedman, C A Lingwood, H M Dosch.   

Abstract

Fresh and transformed human B lineage cells were found to be sensitive to the cytotoxic action of Shiga-like toxin (SLT), a bacterial cytotoxin. The toxin was specifically bound by the glycolipids globotriosylceramide and galabiosylceramide expressed on the surface of sensitive cells. Mutant Daudi cells selected for resistance to SLT cytotoxicity (SLTR20) were deficient in SLT-binding glycolipids and failed to bind SLT to their surface, suggesting a role for these glycolipids in the mediation of SLT cytotoxicity. Of a number of normal and transformed lymphoid and myeloid cells screened for SLT sensitivity, only B lymphoid cells were susceptible to SLT action. Moreover, B lymphoid cells were the only cells expressing the SLT binding glycolipids. In vitro B cell activation studies with Epstein-Barr virus and pokeweed mitogen both indicated that the vast majority of SLT-sensitive B cells belong to the IgG and IgA committed subset, whereas most IgM and IgM/D producing cells were resistant to SLT toxicity. The selective elimination of IgG and IgA committed cells may explain the production of only IgM class anti-SLT antibodies in Shigella-infected humans leading to the failure of long-term immunity to dysenteric disease.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1965141     DOI: 10.1093/intimm/2.1.1

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  35 in total

1.  Shiga toxin 1 from Escherichia coli blocks activation and proliferation of bovine lymphocyte subpopulations in vitro.

Authors:  C Menge; L H Wieler; T Schlapp; G Baljer
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

2.  Induction of verotoxin sensitivity in receptor-deficient cell lines using the receptor glycolipid globotriosylceramide.

Authors:  T Waddell; A Cohen; C A Lingwood
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

3.  Glycolipid modification of alpha 2 interferon binding. Sequence similarity between the alpha 2 interferon receptor and verotoxin (Shiga-like toxin) B-subunit.

Authors:  C A Lingwood; S K Yiu
Journal:  Biochem J       Date:  1992-04-01       Impact factor: 3.857

4.  Neutralization receptor-based immunoassay for detection of neutralizing antibodies to Escherichia coli verocytotoxin 1.

Authors:  J Boulanger; M Petric; C Lingwood; H Law; M Roscoe; M Karmali
Journal:  J Clin Microbiol       Date:  1990-12       Impact factor: 5.948

5.  Comparison of the western blot assay with the neutralizing-antibody and enzyme-linked immunosorbent assays for measuring antibody to verocytotoxin 1.

Authors:  D Reymond; M A Karmali; I Clarke; M Winkler; M Petric
Journal:  J Clin Microbiol       Date:  1997-03       Impact factor: 5.948

6.  Verotoxins inhibit the growth of and induce apoptosis in human astrocytoma cells.

Authors:  S Arab; M Murakami; P Dirks; B Boyd; S L Hubbard; C A Lingwood; J T Rutka
Journal:  J Neurooncol       Date:  1998-11       Impact factor: 4.130

7.  Control of enterohaemorrhagic Escherichia coli infection: the need for a network involving microbiological laboratories and clinical and public health institutions.

Authors:  H Karch
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-04       Impact factor: 3.267

Review 8.  Shiga toxin pathogenesis: kidney complications and renal failure.

Authors:  Tom G Obrig; Diana Karpman
Journal:  Curr Top Microbiol Immunol       Date:  2012       Impact factor: 4.291

9.  A standard immunoglobulin preparation produced from bovine colostra shows antibody reactivity and neutralization activity against Shiga-like toxins and EHEC-hemolysin of Escherichia coli O157:H7.

Authors:  R Lissner; H Schmidit; H Karch
Journal:  Infection       Date:  1996 Sep-Oct       Impact factor: 3.553

10.  Protection by a recombinant Mycobacterium bovis Bacillus Calmette-Guerin vaccine expressing Shiga toxin 2 B subunit against Shiga toxin-producing Escherichia coli in mice.

Authors:  Jun Fujii; Mariko Naito; Takashi Yutsudo; Sohkichi Matsumoto; Daniel P Heatherly; Takeshi Yamada; Hideyuki Kobayashi; Shin-Ichi Yoshida; Tom Obrig
Journal:  Clin Vaccine Immunol       Date:  2012-10-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.